Literature DB >> 15941728

Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab.

I Marie, P Heliot, F Roussel, F Hervé, J F Muir, H Levesque.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15941728     DOI： 10.1093/rheumatology/keh700

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  10 in total

Review 1.  Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.

Authors:  Annette Langer-Gould; Lawrence Steinman
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

2.  Long-standing refractory polymyositis responding to mycophenolate mofetil: a case report and review of the literature.

Authors:  Paola Caramaschi; Alessandro Volpe; Antonio Carletto; Lisa M Bambara; Domenico Biasi
Journal:  Clin Rheumatol       Date:  2007-01-17       Impact factor: 2.980

Review 3.  Treatment of refractory polymyositis and dermatomyositis.

Authors:  Steven R Ytterberg
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

Review 4.  Is continuation of anti-tumor necrosis factor-α therapy a safe option for patients who have developed pulmonary mycobacterial infection? : Case presentation and literature review.

Authors:  Shunsuke Mori; Mineharu Sugimoto
Journal:  Clin Rheumatol       Date:  2011-12-15       Impact factor: 2.980

5.  Importance of T cells, gamma interferon, and tumor necrosis factor in immune control of the rapid grower Mycobacterium abscessus in C57BL/6 mice.

Authors:  Martin Rottman; Emilie Catherinot; Patrick Hochedez; Jean-François Emile; Jean-Laurent Casanova; Jean-Louis Gaillard; Claire Soudais
Journal:  Infect Immun       Date:  2007-09-17       Impact factor: 3.441

6.  Radiological features and therapeutic responses of pulmonary nontuberculous mycobacterial disease in rheumatoid arthritis patients receiving biological agents: a retrospective multicenter study in Japan.

Authors:  Shunsuke Mori; Hitoshi Tokuda; Fumikazu Sakai; Takeshi Johkoh; Akio Mimori; Norihiro Nishimoto; Sadatomo Tasaka; Kazuhiro Hatta; Hidekazu Matsushima; Shunji Kaise; Atsushi Kaneko; Shigeki Makino; Seiji Minota; Takashi Yamada; Shinobu Akagawa; Atsuyuki Kurashima
Journal:  Mod Rheumatol       Date:  2011-12-30       Impact factor: 3.023

Review 7.  Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies.

Authors:  Joerg-Patrick Stübgen
Journal:  J Neurol       Date:  2011-01-21       Impact factor: 6.682

8.  Pulmonary mycobacteriosis caused by Mycobacterium peregrinum: A case report.

Authors:  Yutaka Morita; Yoshihiro Kondo; Eiji Takeuchi
Journal:  Medicine (Baltimore)       Date:  2022-02-11       Impact factor: 1.817

9.  Disseminated Mycobacterium peregrinum and Mycobacterium avium infection in a patient with AIDS: A case report and review of literature.

Authors:  Chong Kei Lao; Ting-Shu Wu; Kuan-Yin Lin; Ming-Hsun Lee
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-04-12

10.  Paradoxical response to disseminated non-tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor-α inhibitor: a case report.

Authors:  Takahiro Takazono; Shigeki Nakamura; Yoshifumi Imamura; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Kakeya; Katsunori Yanagihara; Shigeru Kohno
Journal:  BMC Infect Dis       Date:  2014-02-28       Impact factor: 3.090
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.